PKO Bank Polski - GEDEON RICHTER (RICHT) Gedeon Richter - 1Q19: solid decline of generic business. Results supported by HUF 7.2bn milestone (negative)

Report

PKO Bank Polski

Dawid Górzyński

Gedeon Richter - 1Q19: solid decline of generic business. Results supported by HUF 7.2bn milestone (negative)

Research prepared by PKO BP Securities

10/05/2019 5 EN

Underlying

GEDEON RICHTER

See profile

Provider

PKO Bank Polski

See profile

Analysts

Dawid Górzyński

Other Reports on these Companies

PKO Bank Polski

Gedeon Richter - The FDA approves Vraylar in bipolar depression (positive)

Research prepared by PKO BP Securities

May 28, 2019 May 28, 2019 4 EN

PKO Bank Polski

Gedeon Richter - 1Q19 call: poor FYâ€™19 outlook due to serialization project and cut Esmya sales target (negative)

Research prepared by PKO BP Securities

May 10, 2019 May 10, 2019 4 EN

Famur - Bullish outlook + hard rock entry (positive)

Research prepared by PKO BP Securities

June 5, 2019 June 5, 2019 3 EN

Piotr Łopaciuk

Piotr Łopaciuk

Stalexport - Benefit on VAT exemption? (positive)

Research prepared by PKO BP Securities

June 5, 2019 June 5, 2019 3 EN

Artur Iwański

Artur Iwański

- Dziennik

Research prepared by PKO BP Securities

June 5, 2019 June 5, 2019 10 PL

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Gedeon Richter - 1Q19: solid decline of generic business. Results supported by HUF 7.2bn milestone (negative)

Gedeon Richter - The FDA approves Vraylar in bipolar depression (positive)

Gedeon Richter - 1Q19 call: poor FYâ€™19 outlook due to serialization project and cut Esmya sales target (negative)

Famur - Bullish outlook + hard rock entry (positive)

Stalexport - Benefit on VAT exemption? (positive)

- Dziennik

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe